IL33 in rheumatoid arthritis: potential contribution to pathogenesis.


A better understanding of the inflammatory mechanisms of rheumatoid arthritis and the development of biological therapy revolutionized its treatment, enabling an interference in the synovitis - structural damage - functional disability cycle. Interleukin 33 was recently described as a new member of the interleukin-1 family, whose common feature is its pro… (More)
DOI: 10.1016/j.rbre.2016.03.009